Guangshengtang: the holding subsidiary Litoranavir tablets received the drug registration certificate.

On the evening of May 21, Guangsheng Tang announced that its innovative drug holding subsidiary, Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., has received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for Lopinavir tablets, which will further enhance the company's competitiveness in the antiviral field. Lopinavir tablets are used in combination with other antiretroviral drugs to treat HIV-1 infection in adults and children aged 2 and above.